PtI₂(DACH), the Iodido Analogue of Oxaliplatin as a Candidate for Colorectal

Cancer Treatment: Chemical and Biological Features

D. Cirri,^a S. Pillozzi,^b C. Gabbiani,^c J. Tricomi,^a G. Bartoli,^{a,b} M. Stefanini,^d E. Michelucci,^e A. Arcangeli,^a L. Messori^a* and T. Marzo^{c,a}*

^aLaboratory of Metals in Medicine (MetMed), Department of Chemistry, University of Florence, Via della Lastruccia 3, 50019, Sesto Fiorentino, Italy. E-mail: luigi.messori@unifi.it, tiziano.marzo@unifi.it.

^bDepartment of Experimental and Clinical Medicine, University of Florence, Viale GB Morgagni 50, 50134 Firenze, Italy.

^cDepartment of Chemistry and Industrial Chemistry, University of Pisa, via Moruzzi, 13, 56124 Pisa, Italy. Email: tiziano.marzo@dcci.unipi.it.

^dDIVAL Toscana Srl, Via Madonna del Piano 6, 50119, Sesto Fiorentino, Firenze, Italy.

Mass Spectrometry Centre (CISM), University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Italy.

CONTENTS

¹ HNMR spectrum of PtI ₂ (DACH) in DMF-d ₇ (FIG. S1)	2 2
CNMR spectrum of Ptl ₂ (DACH) in DMF-d ₇ (FIG. S2)	
¹⁹⁵ PtNMR spectrum of PtI ₂ (DACH) in DMF-d ₇ (FIG. S3)	.3
¹ HNMR spectra comparison of PtCl ₂ (DACH) and Ptl ₂ (DACH) in DMF-d ₇ + D ₂ O (FIG. S4)	.3
Synthesis of PtCl2(DACH) (S4)	
interaction with proteins (FIG. S5)	5
ESI-MS theoretical calculations (FIG. S6)	.6
fects of Oxaliplatin and PtI2(DACH) on HCT116 cell proliferation (S7)	7

FIG. S1 ¹HNMR spectrum of PtI₂(DACH) in DMF-d₇ at 400.13 MHz: 5.56 (b, 1H); 4.96 (b, 1H); 2.50 (t, *J* = 8 Hz, 2H); 2.23 (d, *J* = 12 Hz, 2H); 1.56 (m, 4H); 1.15 (m, 2H).



Signals were attributed by comparison with the reported spectrum of oxaliplatin *(Chem. Commun.,* 2012, **48**, 847-849).

FIG. S2 ¹³CNMR spectrum of Ptl₂(DACH) in DMF-d₇ at 100.01 MHz: 65.37; 33.23; 26.03.





FIG. S3 ¹⁹⁵PtNMR spectrum of $PtI_2(DACH)$ in DMF-d₇ at 86.01 MHz: -3413.26.

FIG. S4 ¹HNMR spectra comparison of $PtCl_2(DACH)$ (blue) and $Ptl_2(DACH)$ (red) in DMF-d₇ + D₂O at 400.13 MHz.



 D_2O completely suppress only the -NH₂ signals in the case of chlorido-analogue. This implies a lower mobility of amine protons upon replacement of chlorine with iodide.

S4

Synthesis of PtCl₂(DACH): Diaminocyclohexane (1R,2R)-(-), DACH was solubilised in milli-q water and the obtained solution slowly added to K_2PtCl_4 water solution. After further four hours of stirring precipitate appeared, and complete precipitation of yellow crystals of PtI₂(DACH) allowed over night at room temperature. The solid was then collected through vacuum filtration and washed with hot water and ice-cooled ethanol and ether.

FIG. S5 Interaction with lysozyme and RNase (ESI-MS)



Lvs PtDACH2 1a3 ammacet 72h 37*C_5uM_XT_00001_M_#1 RT: 1.00 AV: 1 NL: 5.59E4 T: FTMS+p ESIFulIms [200.00-3000.00] 100 14303.82871



FIG. S6 ESI-MS theoretical calculations



Comparison between the experimental (upper) and simulated (lower) spectra of 6^{-1} charge state of ODN2 + [Pt(DACH)]²⁺.

S7 Effects of Oxaliplatin and PtI2(DACH) on HCT116 cell proliferation after a single treatment at time 0 (50mM for both compounds), given as the number of Trypan Blue negative cells. Values are means ± sem of three independent experiments.



We studied the antiproliferative effect of Oxaliplatin and PtI2(DACH) on HCT116 cells. The effects of both compounds used at the same concentration (50mM) were tested by the Trypan blue exclusion assay at different incubation times (24, 48, 72 hours). We found that PtI2(DACH) strongly inhibited proliferation, more than oxaliplatin.